Individuals with chronic pain may be driven to smoke more because the analgesic efficacy of nicotine diminishes. To determine whether persistent pain diminishes the actions of a nicotinic acetylcholine receptor (nAChR) agonist in pain modulatory pathways, we examined the effects of epibatidine in the rostral ventromedial medulla (RVM) of rats with and without inflammatory injury induced by intraplantar injection of complete Freund’s adjuvant (CFA). In uninjured rats, epibatidine produced a dose-dependent antinociception that was completely blocked by dihydro-β-erythroidine (DHβE; α4β2 antagonist) and partially blocked by methyllycaconitine (MLA; α7 antagonist). Epibatidine reversed heat hyperalgesia when microinjected in the RVM 4 h, 4 d, or 2 weeks after CFA treatment. Although DHβE completely blocked epibatidine’s antihyperalgesic effect at 4 h, at 2 weeks it elicited only partial antagonism. Methyllycaconitine was ineffective at both time points. Epibatidine’s antinociceptive efficacy in the uninjured hind paw progressively declined, and it was without effect 2 weeks after CFA. Moreover, as early as 4 h after CFA, the antinociceptive effect of epibatidine was no longer antagonized by DHβE. Neither antagonist

Significance Statement

This article presents evidence that, over time, inflammatory injury diminishes the antinociceptive effects of an nAChR agonist in the brainstem and changes the receptors that mediate the agonist’s antihyperalgesic and antinociceptive effects. These data support the clinical hypothesis that those in chronic pain smoke more as a result of a decrease in the analgesic efficacy of nAChR activation.
alone altered paw withdrawal latency in uninjured or CFA-treated rats, suggesting that neither α4β2 nor α7 nAChRs are tonically active in the RVM. The \( B_{\text{max}} \) and \( K_p \) of α4β2 nAChRs in the RVM were unchanged after CFA treatment. These observations provide the first evidence of pharmacological plasticity of the actions of α4β2 nAChR agonists in a critical brainstem pain modulatory pathway and may in part explain why people with chronic pain smoke more than the general population.

**Key words:** antinociception; complete Freund’s adjuvant; epibatidine; nicotinic acetylcholine receptors; rostral ventromedial medulla

**Introduction**

Smoking and chronic pain both present significant health care burdens, and the well-established interaction between the two only worsens the overall toll they exert on both individuals and society (Centers for Disease Control and Prevention, 2004, 2010; Ditre et al., 2011; Institute of Medicine, 2011; World Health Organization, 2011). Observational studies find that smoking rates are positively correlated with pain severity and its resulting functional impairment, and analogously, smoking exacerbates both the intensity and associated impairment of chronic pain (Ditre and Brandon, 2008; Hooten et al., 2011; Patterson et al., 2012). Effectively, a positive feedback loop appears to be initiated: individuals smoke to relieve their pain, smoking exacerbates the pain, and individuals smoke more in response.

In nonsmoking humans, nicotine relieves acute pain and decreases opiate analgesic consumption in the acute postoperative setting (Hong et al., 2008; Yagoubian et al., 2011; Ditre et al., 2016). Nicotine has high affinity for α4β2 nicotinic acetylcholine receptors (nAChRs; Wonnacott and Barik, 2007; Wonnacott, 2014), and nAChR agonists that selectively target α4β2 nAChRs have shown efficacy in clinical trials but with a narrow therapeutic index (Decker et al., 2001; Jones and Dunlop, 2007; Rowbotham et al., 2009, 2012). Studies in rodents suggest that the spinal cord, periaqueductal gray (PAG), and rostral ventromedial medulla (RVM) are important sites of action of nAChR agonists (Umana et al., 2013). Of these, the RVM is of particular interest because it is a critical relay nucleus in endogenous pain modulatory pathways. The RVM receives afferents from more rostral nuclei (e.g., PAG, amygdala) implicated in modulating nociception (Heinricher et al., 2009; Ossipov et al., 2010) and in turn projects directly to the dorsal horn, where it either facilitates or inhibits the transmission of nociceptive information (Ren and Dubner, 1999, 2002; Millan, 2002; Vanegas, 2004; Vanegas and Schaible, 2004). Microinjection of the α4β2 nAChR agonist ABT-594 in the RVM is sufficient to produce antinociception (Bannon et al., 1998). Activation of α4β2 nAChRs specifically in the RVM also appears to be necessary for nicotinic antinociception: inactivation with lidocaine or microinjection of nAChR antagonists in the RVM antagonizes the antinociceptive effects of systemically administered nicotine and epibatidine (Curzon et al., 1998; Decker et al., 1998).

Many hypotheses have been put forward to explain why chronic pain is so poorly managed in smokers. The proposed mechanisms focus largely on biological processes such as inflammation, poor perfusion, ischemia, poor wound healing, nitric oxide production, and nutrition (Ditre et al., 2011). However, little attention has been paid to the role that adaptive changes in the CNS play in this phenomenon. Nociceptive sensitivity reflects the net sum of activity in bulbospinal pain facilitatory and pain inhibitory pathways. Persistent pain states effect substantial changes in the physiology and pharmacology of the bulbospinal pain pathways, altering the balance between facilitation and inhibition (Ren and Dubner, 1999, 2002; Vanegas, 2004; Vanegas and Schaible, 2004). These changes have ramifications for the antinociceptive potency and efficacy of drugs that act in key nuclei, such as enhancement of the antihyperalgesic and antinociceptive effects of µ-opioid receptor agonists in the RVM (Hurley and Hammond, 2001; Schepers et al., 2008).

We hypothesized that persistent pain states may lead to a time-dependent decrease in the antihyperalgesic and antinociceptive efficacy of nAChR agonists in the RVM. This hypothesis was tested by microinjection of epibatidine, a highly potent nAChR agonist, in the RVM of male rats at different times after induction of inflammatory injury by intraplantar injection of complete Freund’s adjuvant (CFA). The pharmacological specificity of epibatidine’s effects and possible tonic activation of nAChRs was further probed using antagonists of the α4β2 and α7 nAChR, which represent the two most abundant subtypes of nAChR in the CNS (Wu and Lukas, 2011; Hurst et al., 2013). As the most parsimonious explanation for a change in agonist action would be a loss of receptor number or decrease in affinity, we additionally conducted radioligand binding studies in rats with and without persistent inflammatory injury. The results of these studies partially support our hypotheses but also suggest alternate mechanisms. Taken together, our findings provide the first evidence of adaptive changes in a critical bulbospinal pathway.
through which nAChR agonists act to modulate nociception and support for the postulate that patients with chronic pain may smoke more because their ongoing pain decreases the analgesic effects of nicotine.

Methods and Materials

Animals
Adult (8–10 weeks of age) male Sprague-Dawley rats weighing 225–275 g were obtained from Charles River. Female rats were not used because the study was initiated before the National Institutes of Health mandated assessment of sex differences. Moreover, the phenotype of nicotine-induced analgesia is more consistent in men than in women (Shi et al., 2010). All experiments were approved by the University of Iowa Animal Care and Use Committee (protocol #4051048) and were conducted based on guidelines set forth by the National Institutes of Health and the International Association for the Study of Pain. After arrival, the animals were acclimated to the facility for at least 48 h before use. Animals were housed two per cage on eighth-inch corn cob bedding (cat. no. 7092; Envigo) in a temperature- and humidity-controlled room on a 12-h light/dark cycle with free access to food and water. After intracerebral cannula placement or intraplantar injection of CFA or saline, the rats were housed individually on the same bedding. Every effort was made to minimize the number of animals used and their suffering.

Experimental design for behavioral studies
The first set of experiments was designed to assess the efficacy and pharmacological specificity of the highly potent nAChR agonist epibatidine microinjected in the RVM of naive rats and rats after different durations of inflammatory injury. Although the investigator could not be blinded to intraplantar treatment, the person testing the rats was blinded to the test drugs, which were made up by another person and assigned a letter that changed throughout the study. The experimental unit was the rat. Although sample size and power were not specifically determined before the study started, the numbers of rats are consistent with previous work from this laboratory.

Model of hind paw inflammatory injury
A single injection of 150 μl CFA (150 μg Mycobacterium butyricum, 85% Drakeol 5NF, and 15% Aralacel A monooate emulsifier; cat. no. 344289; Calbiochem) was made into the plantar surface of the left hind paw of rats lightly anesthetized with isoflurane. Intraplantar injection of CFA induces a robust and reproducible inflammatory injury that begins within 1 h and persists for at least 2 weeks as assessed by paw edema and tests for heat and mechanical hyperalgesia (Nagakura et al., 2003; Hamity et al., 2010). The same volume of physiological saline (0.9%, pH 7.4) was injected in a separate group of animals as a control.

In the CFA model, the withdrawal threshold of the ipsilateral hind paw is greatly diminished, whereas that of the contralateral hind paw is unaffected. Therefore, one can assess the ability of agents to return the threshold of the ipsilateral hind paw to normal values (termed antihyperalgesia) as well as the ability of an agent to further increase the threshold of the contralateral hind paw beyond normal values (termed antinociception). As antihyperalgesia and antinociception are distinct phenomena, comparison of drug effects between ipsilateral and contralateral hind paws is inappropriate. The impact of chronic pain on the antinociceptive effects of drugs (i.e., ability to suppress acute physiological pain) can be assessed by comparison of effects on the contralateral hind paw of CFA-treated rats and naive rats, as well as to the contralateral hind paw of rats with different durations of persistent pain as in this study.

Assessment of nociceptive threshold and paw thickness
Rats were acclimated to the testing environment for 30 min and then placed in individual Plexiglas chambers situated on a glass surface that was maintained at 25°C for another 30-min period of acclimation. Nociceptive sensitivity was measured using the paw withdrawal test, in which a high-intensity beam of light was focused on the plantar surface of the hind paw. The time required for the rat to lift its hind paw from the heat stimulus was termed the paw withdrawal latency (PWL). The high-intensity lamp was adjusted to elicit baseline paw withdrawal latencies of 8–12 s. If a withdrawal response did not occur within 20 s, the test was terminated to prevent tissue injury, and the rat was assigned this latency. Response latencies were determined for the left (injured) and right (uninjured) hind paws. Hind paw thickness in the dorsoventral axis was measured with digital calipers (Ted Pella) before and after intraplantar injection of saline or CFA. All testing was conducted in a small room designated for this work and was completed between the hours of 08:00 and 14:00.

Microinjection studies
Rats were anesthetized with a mixture of ketamine (70 mg/kg i.p.), xylazine (10 mg/kg i.p.), and acepromazine (1 mg/kg i.p.) and implanted with an intracerebral guide cannula positioned above the RVM (26-gauge; Plastics One). Cannulae were affixed to the skull with stainless steel screws and dental acrylic, and a stainless steel styllet was inserted in the guide cannula to maintain patency. Cannulae were implanted 6 to 9 d before behavioral testing. The health status of the rats was monitored daily.

All agents were microinjected in a volume of 0.25 μl via a 33-gauge stainless steel injector needle that extended 3 mm beyond the guide cannula tip. Drug was microinjected over ~10 s, and delivery was monitored by following the movement of an air bubble in the tubing that connected the injector to the syringe pump. The needle was left in place for 60 s after the injection to minimize diffusion of drug up the injection tract. Each rat was used once. Epibatidine (cat. no. E1145; Sigma-Aldrich), dihydro-β-erythroidine (DHβE; cat. no. 2349; Tocris), and methyllycaconitine (MLA; cat. no. M168; Sigma-Aldrich) were dissolved in saline. Saline at pH 7.4 was used as the control for all drugs. Doses of the antagonists were based on prior literature (Panagis et al., 2000; Laviolette and van
After behavioral testing, animals were killed by CO₂ inhalation. Brains were removed, fixed in 10% formalin containing 30% sucrose, and transverse sections cut on a cryostat microtome and stained with Cresyl Violet. Injection sites were identified by two individuals blinded to the behavioral outcome. Microinjection sites that were located in the nucleus reticularis gigantocellularis pars alpha were included with those in the nucleus raphe magnus and collectively referred to as the RVM. Rats were excluded if there was substantial tissue damage at the microinjection site.

Experimental design for radioligand binding studies

Radioligand binding was used to determine and compare the $B_{\text{max}}$ and $K_d$ of α4β2 nAChRs in the RVM 4 h, 4 d, and 2 weeks after intraplantar injection of saline or CFA. An experiment consisted of a cohort of saline- and CFA-treated rats at each of the three time points. Tissue from three rats was pooled to generate a sample, which served as the experimental unit. Three to five independent experiments (biological replicates) were conducted. Although sample size and power were not determined before the study started, the number of replicates is in line with previous work from this laboratory. The individual conducting the binding was blinded to the treatment condition of the homogenates. Rats used for radioligand binding were not subjected to thermal stimuli, as this nociceptive testing has been demonstrated to release endogenous substance P in the RVM (Hamity et al., 2014). In the case of acetylcholine, such release could interfere with determination of $B_{\text{max}}$ and $K_d$. However, paw thickness was measured to confirm the presence of inflammation induced by CFA.

Tissue collection for radioligand binding

Four hours, 4 d, or 2 weeks after intraplantar saline or CFA injection, paw thicknesses were reassessed. The animals were then killed with CO₂, exsanguinated, and decapitated. The brainstem was rapidly dissected out, and two transverse cuts were made 3 and 5 mm rostral to the obex. The resulting 2-mm-thick section was placed on a chilled surface and a triangular region defined at the lateral edge of the pyramids was dissected free. The pyramids were then removed. The resulting region contained the nucleus raphe magnus and the adjacent bilateral nucleus reticularis gigantocellularis pars alpha. The freshly dissected tissue was collected into Eppendorf tubes on ice and stored at –80°C for no more than 2 d before being used to prepare membrane homogenates for radioligand binding.

Membrane homogenate preparation

RVM triangles from three rats in each experimental group were combined, weighed, and thoroughly homogenized in 20 volumes of ice-cold assay buffer (50 mM TRIZMA, pH 7.4; Sigma-Aldrich). The homogenate was then centrifuged at 39,000 $\times g$ at 4°C for 15 min. The supernatant was discarded, 20 volumes of ice cold assay buffer were added, and the pellet was homogenized. The homogenate was incubated at 25°C for 10 min before a second centrifugation step at 39,000 $\times g$ at 4°C for 15 min. The supernatant was again discarded, and the pellet was resuspended in assay buffer. Protein concentration was determined using the Lowry assay. The membrane preparation was stored at –80°C until used for radioligand binding. Membrane preparations were coded to blind the investigator to treatment condition.

Radioligand binding in membrane homogenates

Dilutions of stock $[^3H]$epibatidine (62.2 Ci/mmol, lot #1730657 or 54.1 Ci/mmol, lot #1778835 or #1828391; cat. no. NET1102; Perkin Elmer) were prepared in assay buffer (50 mM TRIZMA, pH 7.4). All reactions were performed in triplicate with 50 µg membrane protein. Binding reactions were terminated by rapid filtration using a Brandel cell harvester and filter paper (Brandel #FP-100 GF/B) that had been soaked in 50 mM TRIZMA, pH 7.2, with 0.5% polyethyleneimine (w/v) at 4°C for at least 2 h to minimize nonspecific binding.

Kinetic assay: association

Test tubes were prepared with 50 µg of membrane protein and final concentrations of 0.002, 0.02, or 0.2 nM $[^3H]$epibatidine. The membranes and radioligand incubated at 25°C in a shaking water bath for 0.5–5 h. Non-specific binding was determined in the presence of 300 µM nicotine (cat. no. N5260; Sigma-Aldrich). Filter discs were washed three times with 5 ml of ice-cold wash buffer (50 mM TRIZMA, pH 7.2), and then placed in scintillation vials to which 500 µl of absolute ethanol was added. Five milliliters of scintillation fluid (Econo-Safe; RPI Corporation) was added 15 min later, and the vials were shaken for 15 min. Samples were left undisturbed for at least 15 h, then were agitated once more and counted using a Beckman Coulter LS6500 scintillation counter at 40% efficiency.

Kinetic assay: dissociation

Test tubes were prepared as described above with a concentration of 0.02 nM $[^3H]$epibatidine. Samples were incubated at 25°C in a shaking water bath for 3 h to allow the binding reaction to reach equilibrium. Dissociation of $[^3H]$epibatidine was then initiated by addition of 300 µM nicotine. The samples were then incubated for an additional 1–11 h. Nonspecific binding was determined at the 3- and 11-h time points in the presence of 300 µM nicotine for the duration of the experiment. The reaction was terminated, and samples were prepared for scintillation analysis as described above.

Saturation assay

Test tubes were prepared as described above with final $[^3H]$epibatidine concentrations ranging from 0.001 to 2.5 nM. Samples were incubated at 25°C in a shaking water bath for 3 h to allow the binding reaction to reach equilibrium. Nonspecific binding was determined in the presence of 300 µM nicotine. The reaction was terminated, and samples were prepared for scintillation analysis as described above. Aliquots of the different $[^3H]$epibatidine dilutions were prepared for scintillation analysis to generate concentration-versus-CPM curves.
Statistical analysis
Microinjection studies
Data were expressed as the mean ± SEM. Two-way repeated-measures ANOVA, in which the repeated factor was time and the other factor was treatment, was used to compare PWL among the different groups. Significant overall effects of treatment or time, or a significant interaction of treatment and time, were followed by the Holm–Sidak test for post hoc comparisons among mean values for the individual treatment groups. Only p values are reported for post hoc tests. Welch’s corrected t-test was used to compare paw thickness at each time point because it does not assume both groups have equal variance. Statistical analyses were conducted with SigmaPlot 13.0, which also indicated that assumptions of normality (Shapiro–Wilk test) and equal variance (Brown–Forsyth test) were met. A p < 0.05 was considered significant for this and all subsequent tests.

Radioligand binding studies
Saturation binding curves of specific binding were fitted by nonlinear regression using GraphPad Prism, and an F-test was conducted to determine whether the curves were best fit by a one- or two-site model. If the data were better fitted by a two-site model, the $B_{\text{max}}$ and $K_d$ for the high-affinity site were used for analysis. The $B_{\text{max}}$ and $K_d$ values were determined for each of three to five independent experiments and were averaged to generate the mean and SEM. Two-way ANOVA in which treatment was one factor and time was the other factor was used to compare $B_{\text{max}}$ and $K_d$ values in saline- and CFA-treated rats at each time point. Superscript letters listed with p-values correspond to the statistical tests shown in Table 1.

Results
Actions of epibatidine in the RVM of naive rats
Microinjection of epibatidine throughout the rostral-caudal extent of the RVM of naive rats produced a dose- and time-dependent increase in PWL (treatment $F_{(4,34)} = 6.208$, $p < 0.001$; time $F_{(4,136)} = 22.363$, $p < 0.001$; interaction $F_{(16,136)} = 2.040$, $p = 0.015$)$^b$ (Fig. 1A and inset). The increase was short-lived, with peak effect observed within 10 min of injection ($p < 0.001$). Fig. 2 depicts the distribution of microinjection sites in the RVM for the 4.11-ng treatment group, which is representative of the distribution of RVM sites in all other treatment groups. In general, microinjection of the highest dose of epibatidine at sites dorsal to or outside the RVM did not increase PWL compared with baseline values ($10.9 ± 0.8$ s at 10 min; $n = 8$; one-way ANOVA $F_{(2,28)} = 0.818$, $p = 0.925$)$^b$, although sites that impinged on the lateral or rostral borders of the RVM could yield modest increases in PWL.

The antinociceptive effect of epibatidine was challenged by pretreatment with 5 μg DHβE, a competitive $\alpha_4\beta_2$ nAChR antagonist (Daly, 2005; Wonnacott and Barik, 2007; Wonnacott, 2014) or 1 μg MLA, a competitive $\alpha_7$ nAChR antagonist (Daly, 2005; Wonnacott and Barik, 2007; Wonnacott, 2014). These two antagonists differentially attenuated the effects of epibatidine (treatment $F_{(2,16)} = 3.696$, $p = 0.048$; time $F_{(4,62)} = 11.328$, $p < 0.001$; interaction $F_{(8,62)} = 2.439$, $p = 0.023$)$^c$. Pretreatment with DHβE completely blocked the antinociceptive effect of the highest dose of epibatidine ($p < 0.001$), whereas challenge with MLA partially attenuated the antinociceptive effects of epibatidine ($p = 0.003$; Fig. 1B). One rat in the latter group adopted a cataleptic stance 45 min after injection, which interfered with PWL measurements at 45 and 60 min. A higher dose of MLA, 3 μg, by itself significantly increased PWL (data not shown), which precluded challenge of epibatidine with a higher dose of MLA. These data suggest an additional involvement of $\alpha_7$ nAChRs in the effects of the highest dose of epibatidine.

To assess whether tonic activation of nAChRs was present, 5 μg DHβE or 1 μg MLA was injected 20 min before microinjection of saline in the RVM. This design mirrored the design used in the pharmacological challenge of epibatidine so that the effect of each antagonist was assessed at the same time point as when its antagonism of epibatidine was determined. Compared with the effect of saline, microinjection of either 5 μg DHβE or 1 μg MLA did not alter PWL (treatment $F_{(1,16)} = 1.181$, $p = 0.332$; interaction $F_{(4,64)} = 1.824$, $p = 0.089$)$^d$, suggesting that little tonic activation of $\alpha_4\beta_2$ or $\alpha_7$ nAChRs exists in the RVM (Fig. 1C). Within-treatment comparison (time $F_{(4,64)} = 10.012$, $p < 0.001$) indicated that microinjection of 5 μg DHβE transiently increased paw withdrawal compared with baseline ($p < 0.001$), whereas saline did not ($p = 0.923$). Nonetheless, the lack of treatment effect does not support tonic activation of $\alpha_4\beta_2$ nAChRs in the RVM.

Impact of peripheral inflammatory injury on the antihyperalgesic and antinociceptive actions of epibatidine in the RVM
Intraplantar injection of CFA in the hind paw uniformly produced robust and reproducible inflammation as indicated by hind paw edema at 4 h, 4 d, and 2 weeks after injection. The thickness of the CFA-injected hind paw was significantly greater than baseline thickness at each time point (4 h: $10.3 ± 0.1$ vs. $6.3 ± 0.1$ (n = 38); 4 d: $9.9 ± 0.2$ vs. $6.0 ± 0.5$ (n = 13); 2 weeks: $9.6 ± 0.2$ vs. $6.2 ± 0.1$ mm (n = 60); 4 h Welch-corrected $t = 69.02$, df = 40.16; 4 d Welch-corrected $t = 17.02$, df = 13.09; 2 weeks Welch-corrected $t = 21.22$, df = 60.11, $p < 0.001$ for all three time points) or the uninflamed, contralateral hind paws (data not shown).

Epibatidine completely reversed heat hyperalgesia within 10 min of its microinjection in the RVM. The effect dissipated over the next 45 min. Of note, epibatidine did not further increase PWL beyond baseline values. The antihyperalgesic effect of epibatidine was unchanged 4 h (treatment $F_{(1,12)} = 28.466$, $p < 0.001$; time $F_{(6,60)} = 22.568$, $p < 0.001$; interaction $F_{(6,60)} = 6.229$, $p < 0.001$)$^f$, 4 d (treatment $F_{(1,11)} = 11.726$, $p = 0.006$; time $F_{(5,54)} = 11.108$, $p < 0.001$; interaction $F_{(5,54)} = 3.272$, $p = 0.012$)$^g$, and 2 weeks (treatment $F_{(1,15)} = 2.431$, $p = 0.140$; time $F_{(7,75)} = 13.682$, $p < 0.001$; interaction $F_{(7,75)} = 2.507$, $p = 0.037$)$^h$ after CFA treatment (Fig. 3A–C). In contrast, the antinociceptive effect of epibatidine in the contralateral, uninflamed hind paw progressively decreased in a time-
| Line | Data structure | Type of test | Power                                                                 |
|------|----------------|--------------|----------------------------------------------------------------------|
| a    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: 0.944  
For time: 1.000  
For interaction: 0.669 |
| b    | Normal distribution | One-way repeated-measures ANOVA (repeated factor: time) | Too small to calculate |
| c    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: 0.458  
For time: 1.000  
For interaction: 0.598 |
| d    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: 0.0734  
For time: 0.999  
For interaction: 0.349 |
| e    | Normal distribution | Welch’s t-test | Four hour 95% CI: 2.7–3.5 mm  
Four day 95% CI: 3.2–3.9 mm  
Two week 95% CI: 3.4–4.5 mm |
| f    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: 0.998  
For time: 1.000  
For interaction: 0.980 |
| g    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: 0.856  
For time: 1.000  
For interaction: 0.959 |
| h    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: 0.846  
For time: 1.000  
For interaction: 0.691 |
| i    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: 0.725  
For time: 1.000  
For interaction: 0.880 |
| j    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: 0.202  
For time: 1.000  
For interaction: 0.501 |
| k    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: 0.115  
For time: 0.961  
For interaction: Too small to calculate |
| l    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: 0.804  
For time: 1.000  
For interaction: 0.250 |
| m    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: 0.250  
For time: 1.000  
For interaction: 0.363 |
| n    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: 0.456  
For time: 1.000  
For interaction: 0.129 |
| o    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: 0.318  
For time: 0.892  
For interaction: 0.194 |
| p    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: too small to calculate  
For time: 1.000  
For interaction: too small to calculate |
| q    | Normal distribution | Two-way repeated-measures ANOVA (repeated factor: time; other factor: treatment) followed by Holm–Sidak test | For treatment: too small to calculate  
For time: 0.730  
For interaction: too small to calculate |
| r    | Normal distribution | Two-way ANOVA (factors: time, treatment) | For treatment: 0.050  
For time: 0.195  
For interaction: 0.050 |
| s    | Normal distribution | Two-way ANOVA (factors: time, treatment) | For treatment: 0.050  
For time: 0.050  
For interaction: 0.050 |
| t    | Normal distribution | Welch’s t-test | Four hour 95% CI: 3.9–4.2 mm  
Four day 95% CI: 3.4–4.4 mm  
Two week 95% CI: 3.1–3.8 mm |

CI, confidence interval.
dependent manner in CFA-treated rats (Fig. 3D–F). As in naive rats, microinjection of 4.11 ng epibatidine in the RVM of rats treated 4 h earlier with CFA significantly increased PWL of the uninjured hind paw for a period of 25 min, with the peak effect at 10 min (treatment $F_{(5,54)} = 11.865, p < 0.001$; interaction $F_{(5,54)} = 5.526, p < 0.001$) (Fig. 3D). When examined 4 d after CFA (Fig. 3E), the magnitude of the increase in PWL was unchanged, but the duration of the effect was truncated (treatment $F_{(1,11)} = 8.903, p = 0.003$; time $F_{(5,54)} = 10.662, p < 0.001$; interaction $F_{(5,54)} = 4.445, p = 0.002$). In rats that had received an injection of CFA 2 weeks earlier, microinjection of 4.11 ng epibatidine in the RVM did not increase PWL in the contralateral hind paw compared to the effects of saline (treatment $F_{(1,15)} = 1.625, p = 0.222$; time $F_{(5,75)} = 5.505, p < 0.001$; interaction $F_{(5,75)} = 0.715, p = 0.614$).

Given that the antihyperalgesic and antinociceptive effects of epibatidine were differently affected in the presence of persistent inflammatory injury, the pharmacological specificity of epibatidine was reexamined both 4 h and 2 weeks after CFA treatment. Four hours after CFA, comparison of the effects of DHβE or MLA to that of saline for the ipsilateral inflamed hind paw (treatment $F_{(2,22)} = 6.596, p = 0.006$; time $F_{(5,110)} = 81.184, p < 0.001$; interaction $F_{(10,110)} = 1.505, p = 0.147$) indicated that challenge with 5 µg DHβE completely blocked the antihyperalgesic effect of epibatidine ($p = 0.003$; Fig. 4A). Challenge with 1 µg MLA did not attenuate the antihyperalgesic effects of epibatidine at this time point ($p = 0.287$).

Surprisingly, analysis of the contralateral uninflamed hind paw (treatment $F_{(2,22)} = 2.291, p = 0.125$; time $F_{(5,110)} = 37.910, p < 0.001$; interaction $F_{(10,110)} = 1.728, p = 0.083$) indicated that neither DHβE ($p = 0.101$) nor MLA ($p = 0.151$) attenuated the antinociceptive effects of epibatidine (Fig. 4B), unlike findings in naive rats (Fig. 1B). These data indicate that the antihyperalgesic effects in the period immediately to injury were predominantly mediated by α4β2 nAChRs, but that the antinociceptive effects of epibatidine were no longer mediated by either α4β2 or α7 nAChRs.
Given that the findings at 4 h suggested alterations in the pharmacology of epibatidine, additional studies were conducted 2 weeks after CFA treatment. At this time (treatment $F_{(2,20)} = 3.584, p = 0.047$; time $F_{(5,100)} = 38.528, p < 0.001$; interaction $F_{(10,100)} = 1.238, p = 0.276$), challenge with 5 $\mu$g DHβE only partially antagonized the antihyperalgesic effects of epibatidine at 10 min ($p = 0.044$ at 10-min time point), and challenge with 1 $\mu$g MLA was ineffective ($p = 0.083$; Fig. 4C). These findings suggest that the antihyperalgesic effect was not substantially mediated by $\alpha_4\beta_2$ or $\alpha_7$ nAChRs. In the presence of DHβE or MLA, epibatidine continued to lack antinociceptive efficacy in the contralateral hind paw (treatment $F_{(2,20)} = 2.719, p = 0.090$; time $F_{(5,85)} = 4.399, p = 0.001$; interaction $F_{(10,85)} = 1.391, p = 0.2195$; Fig. 4D).

To assess the possible development of tonic nAChR activity after inflammatory injury, the effects of the antagonists by themselves were also examined in the RVM of rats that received an intraplantar injection of CFA 2 weeks earlier (Fig. 5A, B). As for the pharmacological challenge of epibatidine, the antagonists were microinjected 20 min before injection of saline at the same site so that their effects could be assessed at the same time. Heat hyperalgesia in the ipsilateral hind paw was unaffected by either DHβE or MLA (treatment $F_{(2,17)} = 0.287, p = 0.754$; time $F_{(5,85)} = 25.112, p < 0.001$; interaction $F_{(10,85)} = 0.576, p = 0.829$) (Fig. 5A). Paw withdrawal latency in the contralateral, uninflamed hind paw was also unaffected by either antagonist (treatment $F_{(2,17)} = 0.281, p = 0.758$; time $F_{(5,85)} = 3.364, p = 0.008$; interaction $F_{(10,85)} = 0.609, p = 0.802$) (Fig. 5B). These data suggest that minimal, if any, tonic activation of $\alpha_4\beta_2$ or $\alpha_7$ nAChRs in the RVM develops as a consequence of persistent inflammatory injury.

**Peripheral inflammatory injury does not alter the number or affinity of $\alpha_4\beta_2$ nAChRs in the RVM**

Initial experiments established optimal assay conditions. Association analysis demonstrated that the amount of $[^{3}H]$epibatidine bound rapidly increased after radioligand addition, and steady-state binding was achieved after $\sim$2 h of incubation (data not shown). As such, a 3-h incubation time was selected for all subsequent experiments. The association constant $k_{on}$ was $1.056 \times 10^{9}$ M$^{-1}$ min$^{-1}$. The amount of bound $[^{3}H]$epibatidine began to decrease immediately after dissociation was induced by the addition of the competing ligand nicotine, and specific binding became negligible after $\sim$11 h (data not shown). The dissociation constant $k_{off}$ was $6.72 \times 10^{-3}$ per min. The binding affinity for epibatidine, $K_a = k_{on} / k_{off}$, was calculated to be $6.37 \text{ pM}$, consistent with values found in the literature (Houghtling et al., 1995; Whiteaker et al., 1998).

Fig. 6 illustrates representative saturation isotherms for $[^{3}H]$epibatidine binding in RVM tissue from saline- and CFA-treated rats. In saline-treated rats, the $B_{max}$ values ranged from 18.9 to 23.6 fmol/mg protein, and the $K_d$ values ranged from 9.8 to 13.7 pm, in good agreement with those calculated using kinetic parameters. Comparison of saturation binding in the RVM of saline- and CFA-treated rats indicated that neither $B_{max}$ (treatment $F_{(1,16)} = 0.024, p = 0.878$; time $F_{(5,16)} = 2.050, p = 0.160$; interaction $F_{(10,16)} = 0.168, p = 0.847$) nor $K_d$ (treatment $F_{(1,16)} = 0.362, p = 0.968$; time $F_{(5,16)} = 0.002, p = 0.702$)
The thickness of the injected hind paws in the cohort of CFA-treated rats used for the binding studies was significantly greater than that of the corresponding hind paw of saline-treated rats [4 h: 9.0 ± 0.2 vs. 5.8 ± 0.1; 4 d: 9.6 ± 0.1 vs. 6.1 ± 0.1; 2 weeks: 10.3 ± 0.2 vs. 6.3 ± 0.1 mm (4 h Welch-corrected t = 17.12, df = 10.59; 4 d Welch-corrected t = 22.54, df = 22.63; 2 weeks Welch-corrected t = 16.44, df = 10.18, p < 0.001 for all three time points; n = 9–15 at each time point)] or the uninflamed, contralateral hind paws (data not shown).
This study first confirmed that the RVM is an important site of action for the antinociceptive effects of nAChR agonists (Iwamoto, 1991; Bitner et al., 1998; Curzon et al., 1998) and characterized the receptor through which epibatidine acts in uninjured rats. Subsequent experiments characterized the ramifications of persistent inflammatory pain on the actions of epibatidine.

**Discussion**

This study first confirmed that the RVM is an important site of action for the antinociceptive effects of α4β2-preferring nAChR agonists (Iwamoto, 1991; Bitner et al., 1998; Curzon et al., 1998) and characterized the receptor through which epibatidine acts in uninjured rats. Subsequent experiments characterized the ramifications of persistent inflammatory pain on the actions of epibatidine.
Epibatidine retained its ability to alleviate heat hyperalgesia as long as 2 weeks after injury. Although mediated by α4β2 nAChRs 4 h after injury, by 2 weeks the antihyperalgesia was no longer substantially mediated by these receptors. Its antinociceptive effect, determined in the contralateral hind paw, was abolished in a time-dependent manner. Moreover, in contrast to naive rats, the antinociceptive effect was no longer mediated by α4β2 nAChRs.

Fig. 5. Persistent inflammatory injury does not establish tonic nicotinic cholinergic signaling in the rostral ventromedial medulla. In rats that received an intraplantar injection of CFA 2 weeks earlier, microinjection of 5 μg DHβE (○, n = 6) or 1 μg MLA (△, n = 6) did not alter either heat hyperalgesia in the ipsilateral, inflamed hind paw (A) or antinociception in the contralateral, uninflamed hind paw (B) compared to saline (●, n = 8). Data are mean ± SEM. BL1 refers to paw withdrawal latency before and BL2 refers to paw withdrawal latency after injection of CFA. ***p < 0.01 compared with BL2 values. Two-way repeated-measures ANOVA followed by Holm–Sidak test.

Fig. 6. Persistent inflammatory injury does not alter the number or affinity of α4β2 nicotinic cholinergic receptors in the rostral ventromedial medulla. Saturation isotherms for binding of [3H]epibatidine to membrane homogenates of the rostral ventromedial medulla of rats 4 h after intraplantar injection of saline (○) or CFA (△) in the hind paw. Symbols represent the mean ± SEM. of triplicate samples. Results from a single representative experiment are illustrated. Specific binding was determined by subtracting nonspecific binding from total binding at each of these concentrations. Specific binding data were fitted using nonlinear regression in GraphPad Prism. Inset, Magnified view of curves at low radioligand concentrations.
nAChRs as early as 4 h after CFA. These changes occurred in the absence of changes in the $B_{\text{max}}$ or $K_u$ of $\alpha 4\beta 2$ nAChRs in the RVM.

**Pharmacology of the antinociceptive effect of epibatidine in the RVM of uninjured rats**

In uninjured rats, microinjection of epibatidine in the RVM dose-dependently increased PWL. As reported (Curzon et al., 1998), the slope of the dose–response curve was relatively shallow and may reflect rapid desensitization of $\alpha 4\beta 2$ nAChRs (Zhang et al., 2012). Also, the first measure of PWL was not made until 10 min after microinjection to minimize any effects of handling. Thus, both the potency and efficacy of epibatidine may be underestimated here.

In terms of affinity and potency, epibatidine is ~300-fold selective for $\alpha 4\beta 2$ over $\alpha 7$ nAChRs (Wonnacott and Barik, 2007). It was used as a pharmacological probe in this study because it is several orders of magnitude more potent than nicotine, which is less selective for $\alpha 4\beta 2$ over $\alpha 7$ nAChRs (Wonnacott and Barik, 2007). The ability of DHβE to completely block effects of epibatidine in the RVM reaffirms (Curzon et al., 1998) that the principal mechanism of action of epibatidine in the RVM entails activation of heteromeric nAChRs, principally $\alpha 4\beta 2$. This subtype accounts for 70%–90% of $[^3H]$nicotinic binding sites in the brain (Daly, 2005; Wonnacott and Barik, 2007; Marks et al., 2010). However, in mouse brain, one-third of the low-affinity epibatidine binding sites are attributed to $\alpha 7$ nAChRs (Marks et al., 2010). The effects of epibatidine were therefore also challenged with the $\alpha 7$ nAChR antagonist, MLA. Interestingly, MLA partially attenuated the effect of epibatidine. Autoradiography has detected only very low levels of $\alpha 7$ nAChRs in the RVM (Mugnaini et al., 2002; Tribollet et al., 2004; Maier et al., 2011; but see Clarke et al., 1985). Thus, $\alpha 7$ nAChRs may make a minor contribution to epibatidine-induced antinociception in the RVM in the uninjured state. Given that $\alpha 7$ nAChRs are expressed in several pain modulatory nuclei that project to the RVM, such as the periaqueductal gray and amygdala (Clarke et al., 1985), systemically administered $\alpha 7$ nAChR agonists may be able to indirectly engage the neural circuitry of the RVM.

MLA also has nanomolar affinity for $\alpha 6\beta 2$ nAChRs, albeit about 30-fold less than for $\alpha 7$ nAChRs (Mogg et al., 2002; Wonnacott and Barik, 2007). The ability of MLA to partially attenuate the effects of epibatidine may therefore also reflect a contribution of $\alpha 6$-containing nAChRs such as $\alpha 3/\alpha 6\beta 2/\beta 3$. The distribution of $\alpha 6$-containing nAChRs in the CNS is highly restricted (Picciotto et al., 2001), and the majority of studies have focused on their role in the presynaptic facilitation of dopamine release in the reward pathways (Yang et al., 2009). However, $\alpha 6$-containing nAChRs have been implicated in nicotine-induced release of norepinephrine in the hippocampus (Azam et al., 2010), and high levels of $\alpha 6$ mRNA are present in the locus coeruleus (Le Novère et al., 1996; Léna et al., 1999). Noradrenergic afferents to the RVM modulate the activity of bulbospinal pain inhibitory and facilitatory neurons in the RVM (Hammond et al., 1980; Sagen and Proudfoot, 1985; Haws et al., 1990; Bie et al., 2003). Thus, it is possible that a component of epibatidine’s effects could be mediated by actions at $\alpha 6$-containing nAChRs (Champtiaux et al., 2002) situated on noradrenergic terminals in the RVM.

**Inflammatory injury changes the mechanism by which epibatidine alleviates hyperalgesia and diminishes its antinociceptive efficacy**

Numerous studies have reported that agonists for $\alpha 4\beta 2$, $\alpha 7$, or $\alpha 3/\alpha 6\beta 2/\beta 3$ nAChRs alleviate hyperalgesia when systemically administered in a number of inflammatory models including CFA, formalin, or carrageenan (Kes-ingland et al., 2000; Medhurst et al., 2008; Feuerbach et al., 2009; Gao et al., 2010; Zhu et al., 2011; AlSharari et al., 2012; Munro et al., 2012; Nirogi et al., 2013). Much less is known about the actions of nAChR agonists selective for receptors containing $\alpha 6$ and $\alpha 6$ subunits, in part because of the absence of selective full agonists. One study has correlated the antinociceptive potency of $\alpha 4\beta 2$ nAChR agonists in the formalin test to their potency to desensitize this receptor, particularly when it contains an $\alpha 5$ subunit (Zhang et al., 2012), and another demonstrated that the anti-allodynic effect of nicotine in the formalin test was dependent on the presence of an $\alpha 5$ subunit (Bagdas et al., 2015). With respect to the $\alpha 6$ subunit, deletion of this subunit greatly diminished the antihyperalgesic effect of nicotine in CFA-treated mice (Wieskopf et al., 2015).

Studies of the antihyperalgesic effects of nAChR agonists have rarely characterized efficacy or potency as a function of time after injury or probed pharmacological specificity any later than 4 d after injury, nor have they investigated actions in supraspinal pain modulatory circuitry. This study demonstrated that epibatidine retained its antihyperalgesic effects for as long as 2 weeks after inflammatory injury. In the period immediate to injury, its antihyperalgesic effect was completely antagonized by DHβE, consistent with activation of $\alpha 4\beta 2$ nAChRs. However, when reassessed 2 weeks later, epibatidine’s antihyperalgesic effect was only partially antagonized by DHβE. Of note, MLA did not antagonize the antihyperal-
gesic effects of epibatidine at either time. The present findings point to a striking change in the mechanism by which epibatidine alleviates hyperalgesia to one that does not involve \( \alpha7 \) or \( \alpha3/\alpha6 \beta2/\beta3 \), and only minimally involves \( \alpha4/\beta2 \) nAChRs, in a key pain modulatory pathway.

In contrast to its antihyperalgesic effects, epibatidine’s antinociceptive efficacy progressively declined such that it was without effect by 2 weeks. These findings are consistent with the proposal that chronic pain conditions lead to a loss of the analgesic efficacy of nicotine. Moreover, as early as 4 h of injury, the antinociceptive effect of epibatidine was no longer mediated by \( \alpha4/\beta2 \) or \( \alpha7 \) nAChRs. Whether this is due to changes in subunit composition, such as a downregulation of \( \alpha5 \) subunits that assemble with \( \alpha4/\beta2 \) subunits, remains to be determined.

**Inflammatory injury and \( \alpha4/\beta2 \) nAChRs in the RVM**

The few studies that have assessed how persistent pain states alter the expression of nAChRs in the CNS confined their analysis to peripheral nerve injury. Spinal nerve ligation did not alter the \( B_{\max} \) or \( K_d \) of epibatidine binding sites in the dorsal horn, but an increase in the ability of nicotine to displace epibatidine suggested a change in receptor subtype (Young et al., 2008). Partial ligation of the sciatic nerve increased binding to \( \alpha4/\beta2 \) nAChRs in the thalamus (Ueda et al., 2010). However, it did not change epibatidine binding in the RVM, as was also observed here with CFA. Chronic constriction injury decreased \( \beta4 \) subunits in hippocampus, thalamus, and spinal cord (Xanthos et al., 2015).

In contrast, inflammatory injury did not change the affinity or number of \( \alpha4/\beta2 \) nAChRs in the RVM. A decrease in the number or affinity of \( \alpha4/\beta2 \) nAChRs therefore does not appear to be responsible for the loss of antinociceptive efficacy or contribute to the change in receptors that mediate its antihyperalgesic effects. However, several caveats should be noted. Changes in receptor number or subunit composition limited to subpopulations of RVM neurons may not have been detected by radioligand binding in tissue homogenates. An example would be a downregulation of \( \alpha5 \) subunits, which can affiliate with \( \alpha4/\beta2 \) nAChRs and contribute to the antinociceptive effects of nicotine (Ramirez-Latorre et al., 1996; Jackson et al., 2010; but see Xanthos et al., 2015). Finally, evidence is accruing for an interaction of nAChRs and G-proteins (Kabbani et al., 2013) such that alterations in subcellular signaling pathways downstream of the receptor may play a role.

**Effect of inflammatory injury on pain modulatory pathways and implications for nicotinic modulation of noiception**

Inflammatory injury may alter the affinity, number, and subtypes of nAChRs through which agonists or endogenously released acetylcholine act to modulate nociception. However, it is also possible that the antihyperalgesic and antinociceptive effects of nAChR agonists are altered independently of changes in the nAChR, as occurred here in the RVM. For example, presynaptic nAChRs promote neurotransmitter release (Picciotto et al., 2012). The antinociceptive and antihyperalgesic effects of nAChR agonists may therefore be altered secondary to injury-induced plasticity in other neurotransmitter systems whose release of nAChRs agonists promote, e.g., a reduction in terminal content of the neurotransmitter or a downregulation of its corresponding receptor. For example, persistent inflammatory injury enhances the antihyperalgesic or antinociceptive actions of opioid, \( \alpha \)-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and N-methyl-\( \alpha \)-aspartate receptor agonists in the RVM (Hurley and Hammond, 2000; Guan et al., 2002, 2003, 2004). A facilitation of opioid peptide or glutamate release in the RVM would be inconsistent with the loss of antinociceptive efficacy of epibatidine. However, prior activation of \( \alpha4/\beta2 \) nAChRs in synaptosomes of the nucleus trigeminal caudalis is reported to increase internalization and functionally downregulate AMPA receptors with a concomitant decrease in excitatory amino acid release (Samengo et al., 2015). If operative in the RVM, an epibatidine-induced decrease in functional AMPA receptors could contribute to a decrement in antinociception. Peripheral stimulation during chronic inflammatory pain states is also associated with release of two pronociceptive neurotransmitters in the RVM: GABA (Gilbert and Franklin, 2001) and substance P (Hamity et al., 2014). Epibatidine-induced augmentation of GABA or substance P release may also contribute to the loss of antinociception. The development of analgesics based on activation of nAChRs for the relief of persistent pain will require a better understanding of how peripheral injury affects the expression of different nAChR subtypes in specific sites, as well how it alters the activity and function of the neurotransmitter systems that these receptors engage.

**Potential ramifications for development of positive allosteric modulators as analgesics**

Positive allosteric modulators (PAMs) for \( \alpha4/\beta2 \) and \( \alpha7 \) nAChRs are a promising approach to potentiate endogenously released acetylcholine or low doses of orthosteric agonists and thereby circumvent the narrow therapeutic index of orthosteric agonists (Lee et al., 2011; Nirogi et al., 2013). Both \( \alpha4/\beta2 \) and \( \alpha7 \) nAChR PAMs are efficacious in certain preclinical pain models (Zhu et al., 2011; Freitas et al., 2013; Bagdas et al., 2016; but see Gao et al., 2010). When administered alone, the efficacy of PAMs is dependent on release of endogenous acetylcholine. In this study, microinjection of DHβE or MLA did not alter PWL in either uninjured rats or CFA-treated rats. These data suggest that there is little to no tonic release of acetylcholine in the RVM that would engage \( \alpha4/\beta2 \) or \( \alpha7 \) nAChRs and that the RVM would be an unlikely site of action for the analgesic effects of systemically administered PAMs.

**Conclusion**

A loss of nAChR agonist efficacy has not been modeled in the preclinical literature to date, and no studies have compared antinociceptive efficacy between uninjured and persistent pain states. At first glance, the loss of antinociceptive efficacy in the face of the retention of antihyperalgesic efficacy appears puzzling. The former is compatible with the hypothesis that persistent pain leads to a loss of nicotine’s analgesic efficacy, but the latter is not. Several possibilities merit consideration and indicate potential avenues of future investigation. First, although the antihyperalgesic efficacy of
epibatidine was retained in these experiments, it is not known whether this is the clinical experience. The extant literature principally concerns nicotine’s effects in the acute and postoperative pain setting. Indeed, the continued presence of chronic pain in smokers and the positive correlation between severity of pain and smoking would suggest that it is not (Bakhshaie et al., 2016). Second, reward and pain modulatory pathways are intimately linked (Navratilova and Porreca, 2014). It remains to be determined whether persistent pain also alters the expression of nAChRs in reward pathways or diminishes the rewarding effects of nicotine, which could drive those with chronic pain to smoke more. Finally, these differential effects also suggest that the RVM circuitry that mediates antihyperalgesia and antinociception can be dissociated. In summary, the present findings are the first evidence in a preclinical model of persistent pain of adaptive changes in a critical nucleus that results in an eventual loss of antinociceptive efficacy of a nAChR agonist and a change in the mechanism by which it produces antihyperalgesia. The exact nature of these changes, how they affect the actions of nicotine and other more subtype selective nAChR agonists in the RVM, as well as systemically administered nicotine, are the focus of ongoing investigation.

References
AlSharari SD, Carroll FI, McIntosh JM, Damaj MI (2012) The antino- ciceptive effects of nicotinic partial agonists varenicline and sazedetidine-A in murine acute and tonic pain models. J Pharmacol Exp Ther 342:742–749. CrossRef Medline
Azam L, Maskos U, Changeux JP, Dowell CD, Christensen S, De Biasi M, McIntosh JM (2010) Conotoxin BuJA(T5A;P6)C: a novel ligand that discriminates between α6β4 and α6β2 nicotinic ace- tylcholine receptors and blocks nicotine-stimulated norepineph- rine release. FASEB J 24:5113–5123. CrossRef
Bagdas D, AlSharari SD, Freitas K, Tracy M, Damaj MI (2015) The role of alpha5 nicotinic acetylcholine receptors in mouse models of chronic inflammatory and neuropathic pain. Biochim Pharmacol 590–600. CrossRef
Bagdas D, Wilkerson JL, Kulikarni A, Toma W, AlSharari S, Gul Z, Lichtman AH, Papke RL, Thakur GA, Damaj MI (2016) The α6α7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflam- matory and neuropathic pain. Br J Pharmacol 173:2506–2520. CrossRef Medline
Bakhshaie J, Ditre JW, Langdon KJ, Asmundson GJ, Paulus DJ, Zvolensky MJ (2016) Pain intensity and smoking behavior among treatment seeking smokers. Psychiatr Res 237:67–71. CrossRef Medline
Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarken PS, Bitner RS, Bannon AW, Decker MW, Holladay MW, Nikkel AL, Bitner RS, Bannon AW, Donnelly-Roberts DL, Puttfarken PS, Kuntzweiler TA, Briggs CA, Williams M, Arneric SP (1998) The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594. J Pharmacol Exp Ther 287:847–853. Medline
Clarke PB, Schwartz RD, Paul SM, Pert CB, Pert A (1985) Nicotinic binding in rat brain: autoradiographic comparison of [3H]nicotinic acetylcholine, [3H]nicotine, and [125I]α-Bungarotoxin. J Neurosci 5:1297–1315.
Cuzron P, Nikkel AL, Bannon AW, Arneric SP, Decker MW (1998) Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (+)-epibatidine in rats. J Pharma- col Exp Ther 287:484–493. Medline
Daly JW (2005) Nicotinic agonists, antagonists, and modulators from natural sources. Cell Mol Neurobiol 25:513–552. CrossRef Medline
Decker MW, Cuzron P, Holladay MW, Nikkel AL, Bitner RS, Bannon AW, Donnelly-Roberts DL, Puttfarken PS, Kuntzweiler TA, Briggs CA, Williams M, Arneric SP (1998) The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594. J Physiol Paris 92:221–224. Medline
Decker MW, Meyer MD, Sullivan JP (2001) The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs 10:1819–1830. CrossRef Medline
Ditre JW, Brandon TH (2008) Pain as a motivator of smoking: effects of pain induction on smoking urge and behavior. J Abnorm Psychol 117:467–472. CrossRef Medline
Ditre JW, Brandon TH, Zale EL, Meagher MM (2011) Pain, nicotine, and smoking: research findings and mechanistic considerations. Psychol Bull 137:1065–1093. CrossRef Medline
Ditre JW, Heckman BW, Zale EL, Kosiba JD, Maisto SA (2016) Acute analgesic effects of nicotine and tobacco in humans: a meta- analysis. Pain 157:1373–1381. CrossRef Medline
Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F, Nozulak J, Enz A, Bilbe G, McAllister K, Hoyer D (2009) The selective nicotinic acetylcholine receptor alpha7 ago- nist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropsychopharmacology 35:264–263. CrossRef Medline
Freitas K, Ghosh S, Ivy Carroll F, Lichtman AH, Imad Damaj M (2013) Effects of alpha7 positive allosteric modulators in murine inflam- matory and chronic neuropathic pain models. Neuropsychopharmacology 65:156–164. CrossRef Medline
Gao B, Hierl M, Clarink K, Juan T, Nguyen H, Valk M, Deng H, Guo W, Lehto SG, Matson D, McDermott JS, Knop J, Gaida K, Cao L, Waldon D, Albrecht BK, Boezio AA, Copeland KW, Harmange JC, Springer SK, Malmberg AB, McDonough SI (2010) Pharmacological effects of nonspecific and subtype-selective nicotinic acetyl- choline receptor agonists in animal models of persistent pain. Pain 149:33–49. CrossRef Medline
Gilbert AK, Franklin KB (2001) QABAergic modulation of descending inhibitory systems from the rostral ventromedial medulla (RVM), Dose-response analysis of nociception and neurological deficits. Pain 90:25–36. Medline
Gao B, Hierl M, Clarink K, Juan T, Nguyen H, Valk M, Deng H, Guo W, Lehto SG, Matson D, McDermott JS, Knop J, Gaida K, Cao L, Waldon D, Albrecht BK, Boezio AA, Copeland KW, Harmange JC, Springer SK, Malmberg AB, McDonough SI (2010) Pharmacological effects of nonspecific and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain. Pain 149:33–49. CrossRef Medline
Guan Y, Guo W, Zou SP, Dubner R, Ren K (2003) Inflammation-induced upregulation of AMPA receptor subunit expression in brain stem pain modulatory circuitry. Pain 104:401–413. Medline

Guan Y, Terayama R, Dubner R, Ren K (2002) Plasticity in excitatory amino acid receptor-mediated descending pain modulation after inflammation. J Pharmacol Exp Ther 300:513–520. Medline

Hamity MV, Walder RY, Hammond DL (2014) Increased neuronal expression of neurokinin-1 receptor and stimulus-evoked internalization of the receptor in the rostral ventromedial medulla of the rat after peripheral inflammatory injury. J Comp Neurol 522:3037–3051. CrossRef Medline

Hamity MV, White SR, Hammond DL (2010) Effects of neurokinin-1 receptor agonism and antagonism in the rostral ventromedial medulla of rats with acute or persistent inflammatory nociception. Neuroscience 165:902–913. CrossRef Medline

Hammond DL, Levy RA, Proudfoot HK (1980) Hypoalgesia following microinjection of noradrenergic antagonists in the nucleus raphe magnus. Pain 9:85–101. Medline

Haws CM, Heinricher MM, Fields HL (1990) Alpha-adrenergic receptor agonists, but not antagonists, alter the tail-flick latency when microinjected into the rostral ventromedial medulla of the lightly anesthetized rat. Brain Res 533:192–195. CrossRef

Heinricher MM, Tavares I, Leith JL, Lumb BM (2009) Descending control of nociception: Specificity, recruitment and plasticity. Brain Res Rev 60:214–225. CrossRef Medline

Hong D, Conelli-Price J, Cheng S, Flood P (2008) Transdermal nicotine patch for postoperative pain management: a pilot dose-escalating study. Anesth Analg 107:1005–1010. CrossRef Medline

Hooten WM, Shi Y, Gazelka HM, Warner JA, Iwamoto ET (1991) Characterization of the antinociception induced by systemic injection of the kappa opioid receptor agonist, [deltal]-fentanyl in the rat. Pain 45:87–95. Medline

Hurley RW, Hammond DL (2000) The analgesic effects of supraspinal mu and delta opioid receptor agonists are potentiated during persistent inflammation. J Neurosci 20:1249–1259. Medline

Hurley RW, Hammond DL (2001) Contribution of endogenous enkephalins to the enhanced analgesic effects of supraspinal mu opioid receptor agonists after inflammatory injury. J Neurosci 21:2536–2545. Medline

Hurst R, Rollema H, Bertrand D (2013) Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Rev 137:22–54. CrossRef Medline

Institute of Medicine (2011) Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, D.C. National Academies Press.

Iwamoto ET (1991) Characterization of the antinociception induced by nicotine in the pedunculopontine tegmental nucleus and the nucleus raphe magnus. J Pharmacol Exp Ther 257:120–133. Medline

Jackson KJ, Marks MJ, Vann RE, Chen X, Gamage TF, Warner JA, Damaj MI (2010) Role of α7 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice. J Pharmacol Exp Ther 334:137–146. CrossRef Medline

Jones PG, Dunlop J (2007) Targeting the cholinergic system as a therapeutic strategy for the treatment of pain. Neuropharmacology 53:197–206. CrossRef Medline

Kabbani N, Nordman JC, Corgiat BA, Veltri DP, Shehu A, Seymour VA, Adams DJ (2013) Are nicotinic acetylcholine receptors coupled to G proteins?. Bioessays 35:1025–1034. CrossRef

Kesingland AC, Gentry CT, Panesar MS, Bowes MA, Vernier JM,Cube R, Walker K, Urban L (2000) Analogous profile of the nicotinic acetylcholine receptor agonists, (−)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain. Pain 86:113–118. CrossRef

Laviolette SR, van der Kooy D (2003) The motivational valence of nicotine in the rat ventral tegmental area is switched from rewarding to aversive following blockade of the α7-subunit-containing nicotinic acetylcholine receptor. Psychopharmacology (Berl) 166:306–313. CrossRef

Le Novère N, Zoli M, Changeux J-P (1996) Neuronal nicotinic receptor α6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur J Neurosci 8:2428–2439. Medline

Lee CH, Zhu C, Malysz J, Campbell T, Shaughnessy T, Honore P, Polakowski J, Gopalakrishnan M (2011) 4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain. Biochem Pharmacol 82:959–966. CrossRef

Léná C, de Kerchove D'Exaerde A, Cordero-Erausquin M, Le Novère N, del Mar Arroyo-Jimenez M, Changeux JP (1999) Diversity and distribution of nicotinic acetylcholine receptors in the locus coeruleus neurons. Proc Natl Acad Sci U S A 96:12126–12131. Medline

Maier DL, Hill G, Ding M, Tuke D, Einstein E, Gurailey D, Gordon JC, Bock MJ, Smith JS, Bialecki R, Eismann M, Elmore CS, Warkheiser JL (2011) Pre-clinical validation of a novel alpha-7 nicotinic receptor radiotracer, [3H]AZ11637326: target localization, biodistribution and ligand occupancy in the rat brain. Neuropharmacology 61:161–171. CrossRef

Marks MJ, Laverty DS, Whiteaker P, Salminen O, Grady SR, McIntosh JM, Collins AC (2010) John Daly’s compound, epibatidine, facilitates identification of nicotinic receptor subtypes. J Mol Neurosci 40:96–104. CrossRef Medline

Medhurst SJ, Hatcher JP, Hille CJ, Bingham S, Clayton NM, Billinton A, Chessell JP (2008) Activation of the alpha7-nicotinic acetylcholine receptor reverses complete Freund-induced mechanical hyperalgesia in the rat via a central site of action. J Pain 9:580–587. CrossRef

Millan MJ (2002) Descending control of pain. Prog Neurobiol 66:355–474. Medline

Mogg AJ, Whiteaker P, McIntosh JM, Marks M, Collins AC, Wonnacott S (2002) Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum. J Pharmacol Exp Ther 302:197–204. CrossRef

Mugnaini M, Tessari M, Tarter G, Merlo Pich E, Chialumera C, Bunnemann B (2002) Upregulation of [3H]methyllycaconitine binding sites following continuous infusion of nicotine, without changes of α7 or α6 subunit mRNA: an autoradiography and in situ hybridization study in rat brain. Eur J Neurosci 16:1633–1646. Medline

Munro G, Hansen R, Erichsen H, Timmermann D, Christensen J, Hansen H (2012) The alpha7 nicotinic ACh receptor agonist compound B and positive allosteric modulator PNU-120596 both alleviate inflammatory hyperalgesia and cytokine release in the rat. Br J Pharmacol 167:421–435. CrossRef Medline

Nagakura Y, Okada M, Kohara A, Kiso T, Toya T, Iwai A, Wanihuchi F, Yamaguchi T (2003) Alloodynia and hyperalgesia in adjuvant-induced arthritic rats: time course of progression and efficacy of analogesics. J Pharmacol Exp Ther 306:490–497. CrossRef Medline

Navratilova E, Porreca F (2014) Reward and motivation in pain and pain relief. Nat Neurosci 17:1304–1312. CrossRef Medline

Nirogi R, Goura V, Abraham R, Jayarajan P (2013) alpha4beta2 neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain. Eur J Pharmacol 712:22–29. CrossRef Medline

Ossipov MH, Dussor GO, Porreca F (2010) Central modulation of pain. J Clin Invest 120:3779–3787. CrossRef Medline

Panagis G, Kastellakis A, Spyракi C, Nomikos G (2000) Effects of methyllycaconitine (MLA), an α7 nicotinic receptor antagonist, on nicotine- and cocaine-induced potentiation of brain stimulation reward. Psychopharmacology (Berl) 149:388–396. Medline

Patterson AL, Grutzner S, Resnick MP, Dobscha SK, Turk DC, Moracchio BJ (2012) Smoking cigarettes as a coping strategy for chronic pain is associated with greater pain intensity and poorer pain-related function. J Pain 13:285–292. CrossRef Medline

Picciotto MR, Caldarone BJ, Brunzell DH, Zachariou V, Stevens TR, King SL (2001) Neuronal nicotinic acetylcholine receptor subunit

January/February 2017 16 New Research

eNeuro.org eNeuro 4(1) e0364-16.2017
Vanegas H, Schaible HG (2004) Descending control of persistent pain: inhibitory or facilitatory? Brain Res Rev 46:295–309. CrossRef Medline

Whiteaker P, Sharples CGV, Wonnacott S (1998) Agonist-induced up-regulation of alpha 4beta 2 nicotinic acetylcholine receptors in M10 cells: pharmacological and spatial definition. Mol Pharmacol 53:980–962.

Wieskopf JS, Mathur J, Limapicchant W, Post MR, Al-Gazzaz M, Sorge RE, Martin LJ, Zaykin DV, Smith SB, Freitas K, Austin JS, Dai F, Zhang J, Marcovitz J, Tuttle AH, Sleipan PM, Clarke S, Drenan RM, Janes J, Al Sharari S, Segall SK, Aasvang EK, Lai W, Bittner R, Richards CI, Slade GD, Kehlet H, Walker J, Maskos U, Changeux JP, Devor M, Maixner W, Diatchenko L, Belfer I, Dougherty DA, Su AI, Lummis SC, Imad Darnaj M, Lester HA, Patapoutian A, Mogil JS (2015) The nicotinic alpha6 subunit gene determines variability in chronic pain sensitivity via cross-inhibition of P2X2/3 receptors. Sci Translat Med 7:287ra272. CrossRef Medline

Wonnacott S (2014) Nicotinic ACh receptors. Tocris Biosci Sci Rev Ser 1–29.

Wonnacott S, Barik J (2007) Nicotinic ACh receptors. Tocris Rev 28:1–20.

World Health Organization (2011) Assessment of the Economic Costs of Smoking. Geneva, Switzerland, WHO.

Wu J, Lukas RJ (2011) Naturally-expressed nicotinic acetylcholine receptor subtypes. Biochem Pharmacol 82:800–807. CrossRef Medline

Xanthos DN, Beiersdorf JW, Thrun A, Ianosi B, Orr-Urtreger A, Huck S, Scholze P (2015) Role of alpha5-containing nicotinic receptors in neuropathic pain and response to nicotine. Neuroparmacology 95:37–49. CrossRef Medline

Yangoubian B, Akkara J, Afzali P, Afti DM, Olson L, Conell-Price J, Yeh J, Eisig SB, Flood P (2011) Nicotine nasal spray as an adjuvant analgesic for third molar surgery. J Oral Max Surg 69:1316–1319. CrossRef Medline

Yang KC, Jin GZ, Wu J (2009) Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology. Acta Pharmacol Sin 30:740–751. CrossRef Medline

Young T, Wittenauer S, Parker R, Vincler M (2008) Peripheral nerve injury alters spinal nicotinic acetylcholine receptor pharmacology. Eur J Pharmacol 590:163–169. CrossRef Medline

Zhang J, Xiao Y-D, Jordan KG, Hammond PS, Van Dyke KM, Mazarov AA, Speake JD, Lippiello PM, James JW, Letchworth SR, Benchfer M, Hauser TA (2012) Analgesic effects mediated by neuronal nicotinic acetylcholine receptor agonists: Correlation with desensitization of alpha4beta2 receptors. Eur J Pharm Sci 47:813–823. CrossRef Medline

Zhu CZ, Chin CL, Rustay NR, Zhong C, Mikusa J, Chandran P, Salyers A, Gomez E, Simler G, Lewis LG, Gauvin D, Baker S, Pai M, Tovcimak A, Brown J, Komater V, Fox GB, Decker MW, Jacobson PB, Gopalakrishnan M, Lee CH, Honore P (2011) Potentiation of analgesic efficacy but not side effects: co-administration of an alpha5beta2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats. Biochem Pharmacol 82:967–976. CrossRef Medline